43572 Federal Register / Vol. 82, No. 179 / Monday, September 18, 2017 / Notices 

for a hearing on the application 

pursuant to 21 CFR 1301.43 on or before 

October 18, 2017. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on April 

19, 2017, Unither Manufacturing LLC, 

331 Clay Road, Rochester, New York 

14623 applied to be registered as an 

importer of methylphenidate (1724), a 

basic class of controlled substance listed 

in schedule II. 

The company plans to import the 

listed substance solely for updated 

analytical testing purposes for EU 

customer requirements. This analysis is 

required to allow the company to export 

domestically-manufactured FDF to 

foreign markets. 

Dated: September 11, 2017. 

Demetra Ashley, 

Acting Assistant Administrator. 

[FR Doc. 2017–19830 Filed 9–15–17; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Sharp Clinical Services, 

Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before October 18, 2017. Such 

persons may also file a written request 

for a hearing on the application on or 

before October 18, 2017. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on August 

23, 2017, Sharp Clinical Services, Inc., 

300 Kimberton Road, Phoenixville, 

Pennsylvania 19460 applied to be 

registered as an importer of the 

following basic classes of controlled 

substances: 

Controlled substance Drug 

code Schedule 

Marihuana ................................ 7360 I 

3,4-Methylenedioxymethamphetamine.7405 I 

Psilocybin ................................. 7437 I 

The company plans to import the 

listed controlled substances for 

analytical research, testing, and clinical 

trials. No other activity for these drug 

codes is authorized for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of FDA approved or nonapproved finished dosage forms for 

commercial sale. 

Dated: September 11, 2017. 

Demetra Ashley, 

Acting Assistant Administrator. 

[FR Doc. 2017–19836 Filed 9–15–17; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Mylan Pharmaceuticals, 

Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before October 18, 2017. Such 

persons may also file a written request 

for a hearing on the application 

pursuant to 21 CFR 1301.43 on or before 

October 18, 2017. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All request for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 


sradovich on DSKBBY8HB2PROD with NOTICES
Federal Register / Vol. 82, No. 179 / Monday, September 18, 2017 / Notices 43573 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on March 

24, 2017, Mylan Pharmaceuticals, Inc., 

2898 Manufacturers Road, Greensboro, 

North Carolina 27406 applied to be 

registered as an importer of nabilone 

(7379), a basic class of controlled 

substance listed in schedule II. 

The company plans to import the 

FDA approved drug product in finished 

dosage form for distribution to its 

customers. Approval of permit 

applications will occur only when the 

registrant’s business activity is 

consistent with what is authorized 

under 21 U.S.C. 952(a)(2). 

Dated: September 11, 2017. 

Demetra Ashley, 

Acting Assistant Administrator. 

[FR Doc. 2017–19832 Filed 9–15–17; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Federal Bureau of Investigation 

[OMB Number 1110–NEW] 

Agency Information Collection 

Activities; Proposed eCollection, 

eComments Requested; Crime Data 

Explorer Feedback Survey 

AGENCY: Federal Bureau of 

Investigation, Department of Justice. 

ACTION: 60-Day notice. 

SUMMARY: The Department of Justice 

(DOJ), Federal Bureau of Investigation 

(FBI), Criminal Justice Information 

Services Division (CJIS), will be 

submitting the following information 

collection request to the Office of 

Management and Budget (OMB) for 

review and approval in accordance with 

the Paperwork Reduction Act of 1995. 

DATES: Comments are encouraged and 

will be accepted for 60 days until 

November 17, 2017. 

FOR FURTHER INFORMATION CONTACT: All 

comments, suggestions, or questions 

regarding additional information, to 

include obtaining a copy of the 

proposed information collection 

instrument with instructions, should be 

directed to Mrs. Amy C. Blasher, Unit 

Chief, Federal Bureau of Investigation, 

Criminal Information Services Division, 

Module E–3, 1000 Custer Hollow Road, 

Clarksburg, West Virginia 26306; 

facsimile (304) 625–3566. 

SUPPLEMENTARY INFORMATION: Written 

comments and suggestions from the 

public and affected agencies concerning 

the proposed collection of information 

are encouraged. Your comments should 

address one or more of the following 

four points: 

—Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the Federal Bureau of 

Investigation, including whether the 

information will have practical utility; 

—Evaluate the accuracy of the agency’s 

estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

—Evaluate whether and if so how the 

quality, utility, and clarity of the 

information to be collected can be 

enhanced; and 

—Minimize the burden of the collection 

of information on those who are to 

respond, including through the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms 

of information technology, e.g., 

permitting electronic submission of 

responses. 

Overview of This Information 

Collection 

1. Type of Information Collection: 

New collection. 

2. The Title of the Form/Collection: 

Crime Data Explorer Feedback Survey. 

3. The agency form number, if any, 

and the applicable component of the 

Department sponsoring the collection: 

No form number. The applicable 

component within the Department of 

Justice is the Criminal Justice 

Information Services Division, in the 

Federal Bureau of Investigation. 

4. Affected public who will be asked 

or required to respond, as well as a brief 

abstract: Primary: Law enforcement, 

academia and the general public. 

Abstract: This survey is needed to 

collect feedback on the functionality of 

the CDE in order to make improvements 

to the application. 

5. An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond: UCR Crime Data Explorer 

Burden Estimation: It is estimated the 

CDE will generate 200 feedback 

responses per year with an estimated 

response time of 2 minutes per 

response. 

6. An estimate of the total public 

burden (in hours) associated with the 

collection: There are approximately 7 

hours, annual burden, associated with 

this information collection. 

If additional information is required 

contact: Melody Braswell, Department 

Clearance Officer, United States 

Department of Justice, Justice 

Management Division, Policy and 

Planning Staff, Two Constitution 

Square, 145 N Street NE., 3E.405A, 

Washington, DC 20530. 

Dated: September 13, 2017. 

Melody Braswell, 

Department Clearance Officer for PRA, U.S. 

Department of Justice. 

[FR Doc. 2017–19814 Filed 9–15–17; 8:45 am] 

BILLING CODE 4410–02–P 

DEPARTMENT OF JUSTICE 

Notice of Lodging of Proposed 

Consent Decree Under the Clean Water 

Act, Clean Air Act, Emergency 

Planning and Community Right-ToKnow Act, and Resource Conservation 

and Recovery Act 

On September 12, 2017, the 

Department of Justice lodged a proposed 

consent decree with the United States 

District Court for the Western District of 

Pennsylvania in the lawsuit entitled 

United States v. StarKist Co. and 

Starkist Samoa Co., Civil Action No. 

2:17–cv–01190–DSC. 

The United States filed this lawsuit 

under the Clean Water Act (CWA), 

Clean Air Act (CAA), Emergency 

Planning and Community Right-toKnow Act (EPCRA), and the Resource 

Conservation and Recovery Act (RCRA). 

The complaint seeks injunctive relief 

and civil penalties for violations of 

these statutes and their implementing 

regulations at defendants’ seafood 

processing and canning facility in 

American Samoa. Specifically, the 

complaint alleges the following CWA 

violations: (1) Unpermitted discharges 

of wastewater through an outfall rupture 

in 2014; (2) violations of terms and 

conditions of the facility’s National 

Pollutant Discharge Elimination System 

Permit, including effluent limit 

violations; and (3) violations of the 

CWA’s Spill Prevention Control and 

Countermeasures regulations related to 

the facility’s oil storage tanks. The 

complaint also alleges violations of the 


sradovich on DSKBBY8HB2PROD with NOTICES